Literature DB >> 3260630

B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

R D Schrier1, J W Gnann, A J Langlois, K Shriver, J A Nelson, M B Oldstone.   

Abstract

Using synthetic peptides, we characterized the B-lymphocyte (antibody) and T-lymphocyte (proliferation) responses to an immunodominant epitope of human immunodeficiency virus type 1 (HIV-1) located near the amino-terminal end of the transmembrane glycoprotein (env amino acids 598 to 609). Both immunoglobulin M (IgM) and IgG antibodies against this epitope appeared early after primary infection with HIV-1. In an animal model, the IgG response to a synthetic peptide derived from this sequence was T-helper-cell dependent, whereas the IgM response was T-cell independent. In addition, antibody generated by immunization with this peptide had HIV-1-neutralizing activity. Greater than 99% (201 of 203) of patients infected with HIV-1 generated antibody to this peptide in vivo; however, only 24% (7 of 29) had T cells that proliferated in response to this peptide in vitro. These observations suggest that different HIV-1 gp41 epitopes elicit B-cell and T-cell immune responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260630      PMCID: PMC253681     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Monoclonal antibodies to gp110 and gp41 of human immunodeficiency virus.

Authors:  L H Gosting; J McClure; E S Dickinson; S M Watanabe; K Shriver; L C Goldstein
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

2.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

3.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

Authors:  B Wahren; L Morfeldt-Månsson; G Biberfeld; L Moberg; A Sönnerborg; P Ljungman; A Werner; R Kurth; R Gallo; D Bolognesi
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

4.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

5.  Antibody response to human immunodeficiency virus after primary infection.

Authors:  D A Cooper; A A Imrie; R Penny
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

6.  HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia.

Authors:  M Robert-Guroff; P J Giardina; W G Robey; A M Jennings; C J Naugle; A N Akbar; R W Grady; M W Hilgartner
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

7.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Authors:  T J Matthews; A J Langlois; W G Robey; N T Chang; R C Gallo; P J Fischinger; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.

Authors:  S Modrow; B H Hahn; G M Shaw; R C Gallo; F Wong-Staal; H Wolf
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

9.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus.

Authors:  J W Gnann; P L Schwimmbeck; J A Nelson; A B Truax; M B Oldstone
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

View more
  28 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

6.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Cross-reactivity of anti-human immunodeficiency virus type 1 gp41 antibodies with human astrocytes and astrocytoma cell lines.

Authors:  T Spehar; M Strand
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.